XM اپنی سروسز امریکہ کے شہریوں کو فراہم نہیں کرتا ہے۔
B
B

Biogen


خبر

Brainy efforts underway, but still some way to go for neuro drug developers

LIVE MARKETS-Brainy efforts underway, but still some way to go for neuro drug developers Main U.S. indexes sharply higher; Nasdaq, Dow up 1.3% Cons Disc leads S&P sector gainers; Utilities sole loser Euro STOXX 600 index up 1.3% Dollar rises; gold edges up; crude, up >1%, bitcoin up 0.4% U.S. 10-Year Treasury yield edges up to ~4.33% Welcome to the home for real-time coverage of markets brought to you by Reuters reporters.
A
B
R
U
U

U.S. Altair Engineering, Brinker International, Meta

U.S. RESEARCH ROUNDUP-Altair Engineering, Brinker International, Meta Oct 31 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Altair Engineering, Brinker International and Meta, on Thursday. HIGHLIGHTS * Altair Engineering Inc ALTR.O : Needham cuts to hold from buy * Blackbaud Inc BLKB.O : Baird cuts to neutral from outperform * Brinker International Inc EAT.N : JP Morgan cuts to neutral from overweight * Comstock Res
A
A
B
B
C
C
E
G
I
M
S
V
V
A
A
C
K
E
C

Biogen Inc reports results for the quarter ended in September 30 - Earnings Summary

Biogen Inc reports results for the quarter ended in September 30 - Earnings Summary Biogen Inc BIIB.OQ reported quarterly adjusted earnings of $4.08​​ per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of $4.36. The mean expectation of twenty nine analysts for the quarter was for earnings of $3.79 per share.
B

Biogen lifts annual profit forecast as new treatments boost earnings

UPDATE 2-Biogen lifts annual profit forecast as new treatments boost earnings Updates shares, adds analyst comment in paragraph 4, CEO comment in paragraph 7 and graphic By Mariam Sunny Oct 30 (Reuters) - Biogen BIIB.O raised its annual profit forecast on Wednesday, as new treatments and cost-cutting measures offset declining sales of its multiple sclerosis drugs.
B
N

Biogen Q3 Adjusted EPS USD 4.08 Vs. IBES Estimate USD 3.79

BRIEF-Biogen Q3 Adjusted EPS USD 4.08 Vs. IBES Estimate USD 3.79 Oct 30 (Reuters) - Biogen Q3 revenue USD 2,500 million vs. IBES estimate USD 2,434 million. Q3 EPS USD 2.66
B

Biogen Says Still Sees FY Rev Down Low-Single Digit Percent, With Core Pharma Rev Roughly Flat

BRIEF-Biogen Says Still Sees FY Rev Down Low-Single Digit Percent, With Core Pharma Rev Roughly Flat Oct 30 (Reuters) - Biogen Inc BIIB.O : BIOGEN Q3 ADJUSTED EPS $4.08 VERSUS IBES ESTIMATE $3.79 BIOGEN OUTLOOK FY ADJUSTED EPS $16.10 TO $16.60 VERSUS PRIOR OUTLOOK $15.75 TO $16.25 BIOGEN FY2024 EPS VIEW $16.19, REVENUE VIEW $9.64 BILLION -- IBES DA
B

Biogen lifts annual profit forecast as cost cuts help

Biogen lifts annual profit forecast as cost cuts help Oct 30 (Reuters) - Biogen BIIB.O raised annual profit forecast and beat third-quarter profit expectations on Wednesday, as its cost-cutting measures helped make up for falling sales of its multiple sclerosis medicines. The drugmaker has cut jobs and pulled the plug on less promising drug candidates in a series of cost-saving measures, focusing on higher-growth products as CEO Christopher Viehbacher takes the lead to bring the cash-strapped bi
B

Alphabet beats and Treasuries rally

MORNING BID AMERICAS-Alphabet beats and Treasuries rally A look at the day ahead in U.S. and global markets from Mike Dolan Markets struggling which way to look will be dizzy again in an event-strewn Wednesday but the spotlight first thing drops on Alphabet's GOOGL.O impressive earnings beat and a relief-rally in election-bruised U.S. Treasuries. A critical fortnight for investors includes next week's U.S.
A
B
B
C
E
G
G
I
M
M
P
U
U
V
V
A
A
K
J
U
U
U
U
G
I
P

Biogen And Neomorph Announce Multi-Target Research Collaboration To Discover And Develop Molecular Glue Degraders For Alzheimer’S, Rare, And Immunological Diseases

BRIEF-Biogen And Neomorph Announce Multi-Target Research Collaboration To Discover And Develop Molecular Glue Degraders For Alzheimer’S, Rare, And Immunological Diseases Oct 29 (Reuters) - Biogen Inc BIIB.O : BIOGEN AND NEOMORPH ANNOUNCE MULTI-TARGET RESEARCH COLLABORATION TO DISCOVER AND DEVELOP MOLECULAR GLUE DEGRADERS FOR ALZHEIMER’S, RARE,
B

What to Watch in the Day Ahead - Wednesday, October 30

What to Watch in the Day Ahead - Wednesday, October 30 The Day Ahead is an email and PDF publication that includes the day's major stories and events, analyses and other features. To receive The Day Ahead, Eikon users can register at DAY/US . Thomson One users can register at RT/DAY/US. All times in ET/GMT On the U.S. economic front, the Commerce Department's Bureau of Economic Analysis' advance estimate of the gross domestic product (GDP) is expected to show that the economy grew at a 3% pace i
B
C
M
S
V
K
K
C

Gradual dosing of Lilly Alzheimer's drug cuts brain-swelling risk, study finds

Gradual dosing of Lilly Alzheimer's drug cuts brain-swelling risk, study finds  By Julie Steenhuysen CHICAGO, Oct 29 (Reuters) - Starting on a more gradual dosing schedule of Eli Lilly's LLY.N Alzheimer's drug Kisunla cut the percentage of patients experiencing potentially serious brain swelling, according to interim results of a late-stage trial presented at a medical meeting on Tuesday.
B

Biogen Appoints Daniel Quirk, MD, As Chief Medical Officer

BRIEF-Biogen Appoints Daniel Quirk, MD, As Chief Medical Officer Oct 29 (Reuters) - Biogen Inc BIIB.O : BIOGEN APPOINTS DANIEL QUIRK, MD, AS CHIEF MEDICAL OFFICER Source text: ID:nGNX7Mg1HF Further company coverage: BIIB.O
B

Coya Therapeutics reports positive immune response, safety in mid-stage Alzheimer's drug trial

Coya Therapeutics reports positive immune response, safety in mid-stage Alzheimer's drug trial By Bhanvi Satija and Christy Santhosh Oct 29 (Reuters) - Coya Therapeutics COYA.O said on Tuesday its experimental Alzheimer's drug was safe and increased levels of a type of immune cells that help prevent neuroinflammation in patients with Alzheimer's disease enrolled in a small, mid-stage trial.
B

Michael Mcdonnell, Executive Vice President And Chief Financial Officer To Retire In February 2025

BRIEF-Michael Mcdonnell, Executive Vice President And Chief Financial Officer To Retire In February 2025 Oct 28 (Reuters) - Biogen Inc BIIB.O : MICHAEL MCDONNELL, EXECUTIVE VICE PRESIDENT AND CHIEF FINANCIAL OFFICER TO RETIRE IN FEBRUARY 2025 BIOGEN INC - ROBIN KRAMER TO SUCCEED MICHAEL MCDONNELL AS BIOGEN CFO Source text: ID:nGNX6xGqF2 Further com
B

Biogen appoints insider as CFO after Michael McDonnell to retire next year

UPDATE 2-Biogen appoints insider as CFO after Michael McDonnell to retire next year Adds background in paragraph 3, details on Kramer in paragraph 6 Oct 28 (Reuters) - Biogen BIIB.O said on Monday insider Robin Kramer will take over as the drugmaker's finance chief after incumbent Michael McDonnell retires at the end of February next year. The appointment of Kramer, who joined Biogen in 2018 and currently serves as its chief accounting officer, comes at a time when the company is aiming for a tu
B

Biogen CFO Michael McDonnell to retire

Biogen CFO Michael McDonnell to retire Oct 28 (Reuters) - Biogen BIIB.O said on Monday Chief Financial Officer Michael McDonnell plans to retire on Feb. 28, 2025. Reporting by Sriparna Roy in Bengaluru; Editing by Shilpi Majumdar
B

AbbVie banks on Alzheimer's therapy with $1.4 billion buy of Aliada

UPDATE 4-AbbVie banks on Alzheimer's therapy with $1.4 billion buy of Aliada Rewrites 1-5 paragraphs to add background, competition Oct 28 (Reuters) - U.S. drugmaker AbbVie ABBV.N said on Monday it will buy Aliada Therapeutics for $1.4 billion in cash, betting on an experimental Alzheimer's treatment still in the early stage of development. AbbVie, with a market value of about a $330 billion, squared off against at least three other pharmaceutical companies interested in Aliada, a person familia
B

Biogen Presents Positive Results From Phase 2 Ignaz Study Of Felzartamab In Iga Nephropathy At American Society Of Nephrology (Asn) Kidney Week 2024

BRIEF-Biogen Presents Positive Results From Phase 2 Ignaz Study Of Felzartamab In Iga Nephropathy At American Society Of Nephrology (Asn) Kidney Week 2024 Oct 26 (Reuters) - Biogen Inc BIIB.O : BIOGEN PRESENTS POSITIVE RESULTS FROM PHASE 2 IGNAZ STUDY OF FELZARTAMAB IN IGA NEPHROPATHY AT AMERICAN SOCIETY OF NEPHROLOGY (ASN) KIDNEY WEEK 2024 BIOGEN
B

What to Watch in the Week Ahead and on Monday, October 28

What to Watch in the Week Ahead and on Monday, October 28 The Day Ahead is an email and PDF publication that includes the day's major stories and events, analyses and other features. To receive The Day Ahead, Eikon users can register at DAY/US . Thomson One users can register at RT/DAY/US. All times in ET/GMT ON MONDAY Ford is expected to report higher third-quarter revenue and profit, aided by sales of its commercial vehicles.
A
A
B
C
C
C
C
D
G
I
J
M
P
P
R
S
K
K
E
R
U

UK approves Lilly's Alzheimer's drug, but deemed 'too expensive' for wide use

UPDATE 4-UK approves Lilly's Alzheimer's drug, but deemed 'too expensive' for wide use Adds Lilly's statement in paragraph 6 and background on EU decision in paragraph 10 Oct 23 (Reuters) - Eli Lilly's LLY.N treatment for early Alzheimer's was deemed too expensive for wide use by UK's cost-effectiveness body on Wednesday, signalling that patients are unlikely to get access following approval by the country's medicines regulator.
B



شرائط

مشہور اثاثے

دستبرداری: XM Group کے ادارے ہماری آن لائن تجارت کی سہولت تک صرف عملدرآمد کی خدمت اور رسائی مہیا کرتے ہیں، کسی شخص کو ویب سائٹ پر یا اس کے ذریعے دستیاب کانٹینٹ کو دیکھنے اور/یا استعمال کرنے کی اجازت دیتا ہے، اس پر تبدیل یا توسیع کا ارادہ نہیں ہے ، اور نہ ہی یہ تبدیل ہوتا ہے یا اس پر وسعت کریں۔ اس طرح کی رسائی اور استعمال ہمیشہ مشروط ہوتا ہے: (i) شرائط و ضوابط؛ (ii) خطرہ انتباہات؛ اور (iii) مکمل دستبرداری۔ لہذا اس طرح کے مواد کو عام معلومات سے زیادہ کے طور پر فراہم کیا جاتا ہے۔ خاص طور پر، براہ کرم آگاہ رہیں کہ ہماری آن لائن تجارت کی سہولت کے مندرجات نہ تو کوئی درخواست ہے، اور نہ ہی فنانشل مارکیٹ میں کوئی لین دین داخل کرنے کی پیش کش ہے۔ کسی بھی فنانشل مارکیٹ میں تجارت میں آپ کے سرمائے کے لئے ایک خاص سطح کا خطرہ ہوتا ہے۔

ہماری آن لائن تجارتی سہولت پر شائع ہونے والے تمام مٹیریل کا مقصد صرف تعلیمی/معلوماتی مقاصد کے لئے ہے، اور اس میں شامل نہیں ہے — اور نہ ہی اسے فنانشل، سرمایہ کاری ٹیکس یا تجارتی مشورے اور سفارشات؛ یا ہماری تجارتی قیمتوں کا ریکارڈ؛ یا کسی بھی فنانشل انسٹرومنٹ میں لین دین کی پیشکش؛ یا اسکے لئے مانگ؛ یا غیر متنازعہ مالی تشہیرات پر مشتمل سمجھا جانا چاہئے۔

کوئی تھرڈ پارٹی کانٹینٹ، نیز XM کے ذریعہ تیار کردہ کانٹینٹ، جیسے: راۓ، خبریں، تحقیق، تجزیہ، قیمتیں اور دیگر معلومات یا اس ویب سائٹ پر مشتمل تھرڈ پارٹی کے سائٹس کے لنکس کو "جیسے ہے" کی بنیاد پر فراہم کیا جاتا ہے، عام مارکیٹ کی تفسیر کے طور پر، اور سرمایہ کاری کے مشورے کو تشکیل نہ دیں۔ اس حد تک کہ کسی بھی کانٹینٹ کو سرمایہ کاری کی تحقیقات کے طور پر سمجھا جاتا ہے، آپ کو نوٹ کرنا اور قبول کرنا ہوگا کہ یہ کانٹینٹ سرمایہ کاری کی تحقیق کی آزادی کو فروغ دینے کے لئے ڈیزائن کردہ قانونی تقاضوں کے مطابق نہیں ہے اور تیار نہیں کیا گیا ہے، اسی طرح، اس پر غور کیا جائے گا بطور متعلقہ قوانین اور ضوابط کے تحت مارکیٹنگ مواصلات۔ براہ کرم یقینی بنائیں کہ آپ غیر آزاد سرمایہ کاری سے متعلق ہماری اطلاع کو پڑھ اور سمجھ چکے ہیں۔ مذکورہ بالا معلومات کے بارے میں تحقیق اور رسک وارننگ ، جس تک رسائی یہاں حاصل کی جا سکتی ہے۔

خطرے کی انتباہ: آپکا سرمایہ خطرے پر ہے۔ ہو سکتا ہے کہ لیورج پروڈکٹ سب کیلیے موزوں نہ ہوں۔ براہ کرم ہمارے مکمل رسک ڈسکلوژر کو پڑھیے۔